Company Insights

ONMD customer relationships

Explore interactive graphBrowse insights index

ONMD customers relationship map

OneMedNet (ONMD): Real‑World Imaging Data, concentrated customers, and a subscriptions pivot

OneMedNet sells regulatory‑grade imaging and clinical records to life‑sciences, device and AI developers through two monetization paths: iRWD™ — fixed‑fee, usage‑based deliveries of curated, de‑identified imaging and clinical data — and BEAM — a subscription imaging exchange platform that the company has been winding down. The firm reported record 2025 bookings of $2.79 million and is executing a deliberate transition toward recurring, contractually predictable iRWD subscriptions and usage fees. Learn more at https://nullexposure.com/

How OneMedNet actually makes money and why the structure matters

OneMedNet’s commercial model is a hybrid of usage‑based data licensing (iRWD) and subscription software (BEAM). The company recognizes iRWD revenue when data deliveries occur under fixed‑fee contracts priced by data unit, while BEAM historically produced ratable subscription revenue invoiced quarterly or annually in advance. Management has been moving away from BEAM and concentrating on iRWD deliveries and subscriptionized iRWD access, a transition reflected in the 2025 bookings announcement. According to OneMedNet’s public disclosures and contemporaneous press coverage, that strategic shift materially altered revenue mix in 2024–2025 and drove acceleration into 2026 (GlobeNewswire, Feb 12, 2026).

Key operating characteristics to keep top of mind:

  • Concentration risk is material: two customers represented 52% of 2024 revenue (35% and 17%), so top‑line volatility tracks the contract timing of a handful of large clients.
  • Contracting posture is mixed: iRWD contracts are effectively usage‑based fixed‑fee deliveries; BEAM was subscription and is being discontinued, which reduces legacy recurring software revenue but focuses management on higher‑value data licensing.
  • Global reach with regional exposure: revenue is reported across Americas and Europe/Middle East, validating a global addressable market while showing meaningful EMEA receipts in recent years.

Customer relationships that move the needle

mlHealth 360 — an active, strategic iRWD subscriber that secured FDA 510(k) clearance

OneMedNet provided the high‑quality, multimodal clinical imaging and contextual data that supported mlHealth 360’s FDA 510(k) clearance for Scaida BrainCT‑ICH, and mlHealth360 signed a multi‑year subscription for continuous access to the iRWD platform to support AI development and validation (press coverage in FY2026; GlobeNewswire, Investing.com, QuiverQuant, SahmCapital, March 2026). These engagements demonstrate direct product validation of OneMedNet data in regulatory submissions and establish a reference customer for future AI diagnostics deals (Barchart and Investing.com, March–May 2026).

Sources: Barchart (news release on Mar 10, 2026); QuiverQuant (news, Mar 10, 2026); GlobeNewswire (Feb 12, 2026); Investing.com (May 3, 2026).

Risorius Co., Ltd. — licensed EEG/PSG waveform and longitudinal clinical context

OneMedNet entered a strategic data‑licensing agreement with Risorius to provide large‑scale EEG and polysomnography (PSG) waveform data paired with clinically meaningful context and longitudinal follow‑up for digital biomarker research across CNS indications (FY2026 press releases). This is a classic iRWD licensing engagement that positions OneMedNet as a supplier to neurotechnology platforms developing EEG‑based biomarkers (QuiverQuant and SahmCapital, February–March 2026).

Sources: QuiverQuant (news, Mar 10, 2026); SahmCapital (news, Feb 24, 2026).

Circle CVI — subscription conversion evidence and pipeline validation

Circle CVI signed a subscription agreement in mid‑2025 as part of the company’s shift toward predictable recurring revenue; management cited this and the mlHealth360 agreement as evidence of a growing pipeline extending into 2026 (GlobeNewswire and SahmCapital, Feb 12, 2026). Circle CVI serves as a visible example of OneMedNet’s ability to convert buyers into subscription customers and to book multi‑period contracts that underpin the bookings headline.

Sources: GlobeNewswire (Feb 12, 2026); SahmCapital (Feb 12, 2026).

Inka Health (Onco‑Innovations Limited subsidiary) — oncology iRWD access partnership

OneMedNet announced a partnership with Inka Health to provide access to its iRWD platform for oncology data needs, reinforcing the company’s foothold in therapeutic‑area licensing for clinical evidence and device/algorithm validation (reported in an SEC‑filings summary and media coverage in FY2026). This engagement underscores OneMedNet’s traction selling disease‑area specific licensing to clinical innovators (Investing.com SEC filings coverage, May 2026).

Source: Investing.com (SEC‑filings coverage, May 3, 2026).

Xylexa — repeat customer testimonial and execution credibility

Xylexa, in remarks tied to RSNA 2025, credited OneMedNet’s speed, curation and regulatory‑grade standards as reasons for repeat engagements, framing OneMedNet as a trusted strategic partner for ongoing evidence generation (SahmCapital, Dec 10, 2025). This qualitative endorsement supports the claim that OneMedNet’s operational execution is a differentiator among life‑science buyers needing clinical imaging paired with context.

Source: SahmCapital (RSNA coverage, Dec 10, 2025).

Operational constraints and strategic signals investors should track

The company disclosures and press reports together reveal a set of company‑level operating signals that determine revenue durability and execution risk:

  • Contract mix: iRWD is sold on a fixed‑fee, unit‑based basis with revenue recognized on delivery; BEAM was subscription‑based and recognized ratably but is being discontinued. This indicates a shift from legacy SaaS revenue toward contractually specific, potentially lumpy data deliveries. (Company filings and product descriptions.)
  • Geographic footprint: OneMedNet reports revenue from Americas and Europe/Middle East, confirming global customer reach while exposing the company to cross‑border regulatory and market execution considerations.
  • Concentration: Two customers made up 52% of 2024 revenue — a material concentration that amplifies revenue sensitivity to contract renewals and timing.
  • Role and segment: OneMedNet operates primarily as a seller of curated clinical images and contextual records (services) while historically hosting a software exchange (BEAM) that management is winding down; expect the company to emphasize services and data licensing as the growth engine.
  • Relationship lifecycle: Management noted BEAM discontinuation reduced subscription renewals, while iRWD deliveries drove increased active customer deliveries in the period; that reflects a portfolio transition from legacy software to active data licensing.

These constraints signal a company in tactical transition: execution quality and the conversion of pilot engagements into multi‑year data contracts determine whether the bookings growth converts into stable recurring revenue.

Explore deeper model and customer analytics at https://nullexposure.com/

Investment implications and short watchlist

  • Upside: Validation of iRWD in FDA submissions (mlHealth360) is a tangible commercial proof point that should accelerate payers and developers to license regulatory‑grade imaging and contextual records. Record 2025 bookings ($2.79M) show demand exists when OneMedNet sells toward regulated use cases.
  • Risk: High customer concentration and the BEAM wind‑down create near‑term revenue volatility; a small number of renewals or non‑renewals can swing results materially.
  • Execution hinge: Growth requires converting reference wins into standardized multi‑year iRWD subscriptions rather than one‑off deliveries; the shift in contract mix increases the importance of robust customer success and predictable contract structures.
  • Watch items: new multi‑year iRWD agreements, renewal cadence of the two large customers, further regulatory‑use case citations (FDA or CE), and quarterly recognition impact from usage‑based deliveries.

OneMedNet’s current trajectory is clear: the company is repositioning as a premium provider of regulatory‑grade imaging and clinical evidence, trading a legacy exchange product for higher‑value licensing engagements that are validated by regulatory milestones and strategic partnerships. Investors should price the share around the probability of scaling repeatable subscription and usage revenues and de‑risking customer concentration through a broader commercial pipeline.

Join our Discord